Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 3/20 | 0.34 |
| ▸ | EED | O75530 | 1/20 | 0.34 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.34 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.34 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.34 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | NMT1 | P30419 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19170395 | 0.89 | LMNA (0.36) | LMNAMERTKEEDRBBP4SUZ12 | |
| SCHEMBL6155541 | 0.87 | LMNA (0.40) | LMNASMN1; SMN2POLBL3MBTL1ALDH1A1 | |
| SCHEMBL19170670 | 0.86 | LMNA (0.38) | LMNAMERTKEEDRBBP4SUZ12 | |
| SCHEMBL17458967 | 0.86 | LMNA (0.44) | LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL16985416 | 0.81 | SMN1; SMN2 (0.38) | CYP3A4CYP2C9SMN1; SMN2EEDRBBP4 | |
| SCHEMBL17458949 | 0.81 | PKM (0.45) | LMNACYP2C9SMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL21961414 | 0.79 | MERTK (0.35) | LMNACYP3A4CYP2C9PRKCQMERTK | |
| SCHEMBL19222864 | 0.78 | CRHR1 (0.40) | LMNAMERTKEEDRBBP4SUZ12 | |
| SCHEMBL19163453 | 0.78 | MCOLN3 (0.40) | LMNASMN1; SMN2L3MBTL1ALDH1A1MEN1 | |
| SCHEMBL17610427 | 0.76 | CHRNB2 (0.41) | CYP2C9SMN1; SMN2POLBL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107074814-A | Glucose transport inhibitor | 拜耳制药股份公司 | 2017-08-18 | — | — | CN | disclosed |
| US-20170226081-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-10 | — | — | US | disclosed |
| US-20170226081-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-10 | — | — | US | disclosed |
| US-20170210738-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-27 | — | — | US | disclosed |
| US-20170210738-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-27 | — | — | US | disclosed |
| US-20170210738-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-27 | — | — | US | disclosed |
| EP-3172194-A1 | GLUCOSE TRANSPORT INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2017-05-31 | — | — | EP | disclosed |
| EP-3172192-A1 | GLUCOSE TRANSPORT INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2017-05-31 | — | — | EP | disclosed |
| CN-106687455-A | Glucose transport inhibitors | 拜耳制药股份公司 | 2017-05-17 | — | — | CN | disclosed |
| WO-2016012481-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | WO | disclosed |
| WO-2016012474-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226081-A1 | GLUCOSE TRANSPORT INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | LMNA 2540/4885CYP3A4 940/4885CYP2C9 944/4885 |
| US-20170210738-A1 | GLUCOSE TRANSPORT INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | LMNA 2878/4885CYP3A4 689/4885CYP2C9 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.